CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis - PubMed (original) (raw)
. 1998 Apr 15;160(8):3627-30.
Affiliations
- PMID: 9558060
CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis
S Zimmermann et al. J Immunol. 1998.
Abstract
Synthetic oligodeoxynucleotides containing CpG dinucleotides (CpG-ODN) mimic the immunostimulatory qualities of bacterial DNA. We asked whether immunostimulation by CpG-ODN predisposes for a commitment toward a Th1 vs a Th2 response in Leishmania major infection, a model for a lethal Th2-driven disease, in BALB/c mice. CpG-ODN induced Th1 effector T cells in vitro and conveyed protective immunity to disease-prone BALB/c mice in vivo. Conversion to a Th1-driven resistant phenotype was associated with IL-12 production and maintained the expression of IL-12R beta2-chains. Most strikingly, CpG-ODN were even curative when given as late as 20 days after lethal L. major infection, indicating that CpG-ODN revert an established Th2 response. These findings imply an important role of bacterial DNA and CpG-ODN in the instruction of adaptive immune responses. They also point to the therapeutic potential of CpG-ODN in redirecting curative Th1 responses in Th2-driven disorders.
Similar articles
- Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N, Mukherjee S, Das L, Das PK. Datta N, et al. Eur J Immunol. 2003 Jun;33(6):1508-18. doi: 10.1002/eji.200323671. Eur J Immunol. 2003. PMID: 12778468 - IL-18 gene therapy develops Th1-type immune responses in Leishmania major-infected BALB/c mice: is the effect mediated by the CpG signaling TLR9?
Li Y, Ishii K, Hisaeda H, Hamano S, Zhang M, Nakanishi K, Yoshimoto T, Hemmi H, Takeda K, Akira S, Iwakura Y, Himeno K. Li Y, et al. Gene Ther. 2004 Jun;11(11):941-8. doi: 10.1038/sj.gt.3302240. Gene Ther. 2004. PMID: 14985787 - The Th1/Th2 paradigm and experimental murine leishmaniasis.
Lohoff M, Gessner A, Bogdan C, Röllinghoff M. Lohoff M, et al. Int Arch Allergy Immunol. 1998 Mar;115(3):191-202. doi: 10.1159/000023900. Int Arch Allergy Immunol. 1998. PMID: 9531160 Review. - Reversal of polarized T helper 1 and T helper 2 cell populations in murine leishmaniasis.
Coffman RL, Correa-Oliviera R, Mocci S. Coffman RL, et al. Ciba Found Symp. 1995;195:20-5; discussion 25-33. doi: 10.1002/9780470514849.ch3. Ciba Found Symp. 1995. PMID: 8724828 Review.
Cited by
- Flublok Quadrivalent Vaccine Adjuvanted with R-DOTAP Elicits a Robust and Multifunctional CD4 T Cell Response That Is of Greater Magnitude and Functional Diversity Than Conventional Adjuvant Systems.
White CL, Glover MA, Gandhapudi SK, Richards KA, Sant AJ. White CL, et al. Vaccines (Basel). 2024 Mar 7;12(3):281. doi: 10.3390/vaccines12030281. Vaccines (Basel). 2024. PMID: 38543915 Free PMC article. - Nanoparticle-Conjugated Toll-Like Receptor 9 Agonists Improve the Potency, Durability, and Breadth of COVID-19 Vaccines.
Ou BS, Baillet J, Picece VCTM, Gale EC, Powell AE, Saouaf OM, Yan J, Nejatfard A, Lopez Hernandez H, Appel EA. Ou BS, et al. ACS Nano. 2024 Jan 30;18(4):3214-3233. doi: 10.1021/acsnano.3c09700. Epub 2024 Jan 12. ACS Nano. 2024. PMID: 38215338 Free PMC article. - Hacking the Immune Response to Solid Tumors: Harnessing the Anti-Cancer Capacities of Oncolytic Bacteria.
Roe JM, Seely K, Bussard CJ, Eischen Martin E, Mouw EG, Bayles KW, Hollingsworth MA, Brooks AE, Dailey KM. Roe JM, et al. Pharmaceutics. 2023 Jul 21;15(7):2004. doi: 10.3390/pharmaceutics15072004. Pharmaceutics. 2023. PMID: 37514190 Free PMC article. Review. - Discovery of pyrazolopyrrolidinones as potent, broad-spectrum inhibitors of Leishmania infection.
Kavouris JA, McCall LI, Giardini MA, De Muylder G, Thomas D, Garcia-Pérez A, Cantizani J, Cotillo I, Fiandor JM, McKerrow JH, De Oliveira CI, Siqueira-Neto JL, González S, Brown LE, Schaus SE. Kavouris JA, et al. Front Trop Dis. 2023;3:1011124. doi: 10.3389/fitd.2022.1011124. Epub 2023 Jan 23. Front Trop Dis. 2023. PMID: 36818551 Free PMC article. - MyD88-dependent signaling drives toll-like receptor-induced trained immunity in macrophages.
Owen AM, Luan L, Burelbach KR, McBride MA, Stothers CL, Boykin OA, Sivanesam K, Schaedel JF, Patil TK, Wang J, Hernandez A, Patil NK, Sherwood ER, Bohannon JK. Owen AM, et al. Front Immunol. 2022 Nov 11;13:1044662. doi: 10.3389/fimmu.2022.1044662. eCollection 2022. Front Immunol. 2022. PMID: 36439136 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources